|
GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
|
WO2007001448A2
(en)
*
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
|
WO2007070682A2
(en)
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
|
CA2648099C
(en)
|
2006-03-31 |
2012-05-29 |
The Brigham And Women's Hospital, Inc |
System for targeted delivery of therapeutic agents
|
|
WO2007137117A2
(en)
*
|
2006-05-17 |
2007-11-29 |
Massachusetts Institute Of Technology |
Aptamer-directed drug delivery
|
|
WO2007150030A2
(en)
*
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
|
WO2008019142A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Massachusetts Institute Of Technology |
Oligonucleotide systems for targeted intracellular delivery
|
|
US10568860B2
(en)
*
|
2006-08-30 |
2020-02-25 |
Kowa Co., Ltd. |
Pharmaceutical composition containing statin-encapsulated nanoparticle
|
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US20100303723A1
(en)
*
|
2006-11-20 |
2010-12-02 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
|
US20110033528A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Poniard Pharmaceuticals, Inc. |
Stabilized picoplatin oral dosage form
|
|
EP2134830A2
(en)
|
2007-02-09 |
2009-12-23 |
Massachusetts Institute of Technology |
Oscillating cell culture bioreactor
|
|
JP2010523595A
(ja)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリ（アミノ酸）ターゲッティング部分
|
|
ES2700234T3
(es)
*
|
2007-06-26 |
2019-02-14 |
Univ Johns Hopkins |
Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
|
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
US20100310661A1
(en)
*
|
2007-07-16 |
2010-12-09 |
Poniard Pharmaceuticals, Inc. |
Oral formulations for picoplatin
|
|
PL2187965T3
(pl)
|
2007-08-17 |
2020-05-18 |
Purdue Research Foundation |
Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
|
|
EP2436376B1
(en)
|
2007-09-28 |
2014-07-09 |
BIND Therapeutics, Inc. |
Cancer cell targeting using nanoparticles
|
|
JP2011500569A
(ja)
|
2007-10-12 |
2011-01-06 |
マサチューセッツ インスティテュート オブ テクノロジー |
ワクチンナノテクノロジー
|
|
US9422234B2
(en)
*
|
2007-11-30 |
2016-08-23 |
The Johns Hopkins University |
Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
|
|
CA2715348A1
(en)
*
|
2008-02-08 |
2009-08-13 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin and bevacizumab to treat colorectal cancer
|
|
US8034396B2
(en)
*
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
EP2282771B1
(en)
*
|
2008-04-28 |
2014-06-25 |
Novartis AG |
Method for producing nanoparticles
|
|
EA020954B1
(ru)
|
2008-06-16 |
2015-03-31 |
Бинд Терапьютикс, Инк. |
Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
|
|
WO2010005726A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
US8318211B2
(en)
|
2008-06-16 |
2012-11-27 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
|
|
PT2318366T
(pt)
|
2008-08-01 |
2017-08-02 |
Univ Johns Hopkins |
Agentes de ligação a psma e suas utilizações
|
|
WO2010027428A1
(en)
|
2008-08-26 |
2010-03-11 |
Massachusetts Institute Of Technology |
Platinum ( iv) complexes for use in dual mode pharmaceutical therapy
|
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
|
US8603532B2
(en)
|
2008-10-20 |
2013-12-10 |
Massachusetts Institute Of Technology |
Nanostructures for drug delivery
|
|
US8563041B2
(en)
*
|
2008-12-12 |
2013-10-22 |
Bind Therapeutics, Inc. |
Therapeutic particles suitable for parenteral administration and methods of making and using same
|
|
WO2010068899A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Creighton University |
Nanoparticles comprising combinations of antiretroviral agents and use thereof
|
|
JP2012512175A
(ja)
*
|
2008-12-15 |
2012-05-31 |
バインド バイオサイエンシズ インコーポレイテッド |
治療薬を徐放するための長時間循環性ナノ粒子
|
|
EP2210584A1
(en)
*
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
|
US8535477B2
(en)
*
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
US8969473B2
(en)
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Compounds and medical devices activated with solvophobic linkers
|
|
WO2010095047A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
|
|
AU2010215196B2
(en)
|
2009-02-21 |
2015-04-16 |
Covidien Lp |
Crosslinked fibers and method of making same by extrusion
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
CA2753162A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
EP2398584A2
(en)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
|
|
US8877170B2
(en)
*
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
US8968733B2
(en)
*
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
WO2010096654A1
(en)
|
2009-02-21 |
2010-08-26 |
Tyco Healthcare Group Lp |
Medical devices having activated surfaces
|
|
CA2753171A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same using uv radiation
|
|
US8663689B2
(en)
*
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
AU2010215931A1
(en)
|
2009-02-21 |
2011-10-13 |
Covidien Lp |
Medical devices having activated surfaces
|
|
EP2398850B1
(en)
|
2009-02-21 |
2018-08-22 |
Sofradim Production |
Medical devices with an activated coating
|
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
|
CN101536982B
(zh)
*
|
2009-04-27 |
2011-11-09 |
中国人民解放军第二军医大学 |
Trastuzumab修饰的包裹毒素蛋白的PEG化免疫脂质体及其制备与应用
|
|
WO2011005363A2
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2011017297A2
(en)
|
2009-08-03 |
2011-02-10 |
The University Of North Carolina At Chapel Hill |
Biodegradable delivery system complexes for the delivery of bioactive compounds
|
|
US12083191B2
(en)
|
2009-10-19 |
2024-09-10 |
Case Western Reserve University |
Composition and methods for imaging cells
|
|
US20130115295A1
(en)
*
|
2009-11-22 |
2013-05-09 |
Qiang Wang |
Rare Earth-Doped Up-Conversion Nanoparticles for Therapeutic and Diagnostic Applications
|
|
DK2509634T3
(en)
|
2009-12-11 |
2019-04-23 |
Pfizer |
Stable formulations for lyophilization of therapeutic particles
|
|
EA201290497A1
(ru)
*
|
2009-12-15 |
2013-01-30 |
Байнд Байосайенсиз, Инк. |
Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
|
|
WO2011084521A2
(en)
*
|
2009-12-15 |
2011-07-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
|
|
EP2515942B1
(en)
|
2009-12-15 |
2020-02-12 |
Pfizer Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
US9951324B2
(en)
|
2010-02-25 |
2018-04-24 |
Purdue Research Foundation |
PSMA binding ligand-linker conjugates and methods for using
|
|
US8795331B2
(en)
|
2010-03-25 |
2014-08-05 |
Covidien Lp |
Medical devices incorporating functional adhesives
|
|
US9272074B2
(en)
*
|
2010-03-25 |
2016-03-01 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
US9168225B2
(en)
|
2010-04-23 |
2015-10-27 |
The Board Of Trustees Of The University Of Illinois |
Nano-hybrid delivery system for sequential utilization of passive and active targeting
|
|
CN103002921A
(zh)
|
2010-05-14 |
2013-03-27 |
马林克罗特有限公司 |
用于联合的光学成像和治疗的功能性交联纳米结构
|
|
AU2011276443A1
(en)
|
2010-06-29 |
2013-01-31 |
Covidien Lp |
Microwave-powered reactor and method for in situ forming implants
|
|
WO2012001532A2
(en)
|
2010-07-01 |
2012-01-05 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
WO2012014080A2
(en)
|
2010-07-27 |
2012-02-02 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9549901B2
(en)
|
2010-09-03 |
2017-01-24 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20150056300A1
(en)
*
|
2010-10-22 |
2015-02-26 |
Bind Therapeutics, Inc. |
Therapeutic nanoparticles with high molecular weight copolymers
|
|
WO2012059936A1
(en)
|
2010-11-03 |
2012-05-10 |
Padma Venkitachalam Devarajan |
Pharmaceutical compositions for colloidal drug delivery
|
|
EP2645991B1
(en)
|
2010-12-02 |
2020-02-12 |
GreenMark Biomedical Inc. |
Aptamer bioconjugate drug delivery device
|
|
US10363309B2
(en)
|
2011-02-04 |
2019-07-30 |
Case Western Reserve University |
Targeted nanoparticle conjugates
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US20140308363A1
(en)
*
|
2011-05-31 |
2014-10-16 |
Bind Therapeutics, Inc. |
Drug loaded polymeric nanoparticles and methods of making and using same
|
|
CN103917227A
(zh)
|
2011-06-21 |
2014-07-09 |
麻省理工学院 |
用于治疗癌症的组合物和方法
|
|
US9605304B2
(en)
*
|
2011-07-20 |
2017-03-28 |
The Hong Kong Polytechnic University |
Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2747761A1
(en)
*
|
2011-09-22 |
2014-07-02 |
Bind Therapeutics, Inc. |
Methods of treating cancers with therapeutic nanoparticles
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
|
EP2725103A3
(en)
*
|
2011-11-14 |
2016-01-06 |
Silenseed Ltd |
Methods and compositions for treating prostate cancer
|
|
AU2012318273B2
(en)
*
|
2011-12-02 |
2016-05-19 |
Greenmark Biomedical Inc. |
Aptamer bioconjugate drug delivery device
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
JP6375289B2
(ja)
|
2012-04-05 |
2018-08-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
免疫刺激組成物およびその使用方法
|
|
US9597385B2
(en)
|
2012-04-23 |
2017-03-21 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
|
US8729286B2
(en)
|
2012-05-10 |
2014-05-20 |
Massachusetts Institute Of Technology |
Platinum compounds as treatment for cancers, and related methods, kits, and compositions
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN104736181A
(zh)
|
2012-08-10 |
2015-06-24 |
北德克萨斯大学健康科学中心 |
包含靶向聚氨基酸与脂肪酸之缀合物的药物递送载剂
|
|
JP2014051478A
(ja)
*
|
2012-09-10 |
2014-03-20 |
Panasonic Corp |
機能性物質、生体活性用薬剤及び機能性物質の生体内への浸透方法、並びに機能性物質放散装置及び空気清浄装置
|
|
WO2014043618A1
(en)
|
2012-09-17 |
2014-03-20 |
Bind Therapeutics, Inc. |
Process for preparing therapeutic nanoparticles
|
|
WO2014059022A1
(en)
*
|
2012-10-09 |
2014-04-17 |
The Brigham And Women's Hospital, Inc. |
Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
|
|
US9801953B2
(en)
|
2012-10-15 |
2017-10-31 |
Emory University |
Nanoparticles carrying nucleic acid cassettes for expressing RNA
|
|
EP2911701A4
(en)
*
|
2012-10-23 |
2016-06-08 |
Univ Johns Hopkins |
Novel self-assembling drug amphiphiles and methods for synthesis and application
|
|
EA201590783A1
(ru)
*
|
2012-11-15 |
2015-11-30 |
Эндосайт, Инк. |
Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
JP6118914B2
(ja)
*
|
2012-12-28 |
2017-04-19 |
ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
放出制御型の固体ポリマーナノ粒子
|
|
EP2950785A4
(en)
|
2013-02-04 |
2016-09-21 |
Univ Notre Dame Du Lac |
NANOPARTICLE-drug delivery systems
|
|
WO2014127365A1
(en)
*
|
2013-02-15 |
2014-08-21 |
Case Western Reserve University |
Psma ligands and uses thereof
|
|
US12465651B2
(en)
|
2013-02-15 |
2025-11-11 |
Case Western Reserve University |
Photodynamic therapy composition
|
|
US11975074B2
(en)
|
2013-02-15 |
2024-05-07 |
Case Western Reserve University |
Photodynamic therapy composition
|
|
US10207005B2
(en)
|
2013-02-15 |
2019-02-19 |
Case Western Reserve University |
Photodynamic therapy composition
|
|
CZ308409B6
(cs)
*
|
2013-02-26 |
2020-08-05 |
Elmarco S.R.O. |
Přípravek pro aplikaci alespoň jedné biologicky a/nebo farmaceuticky aktivní látky
|
|
WO2014160216A2
(en)
|
2013-03-13 |
2014-10-02 |
Massachusetts Institute Of Technology |
Dual targeting anticancer agents
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EA201591762A1
(ru)
|
2013-03-14 |
2015-12-30 |
Ридженерон Фармасьютикалз, Инк. |
Человеческие антитела к grem1
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
KR102233251B1
(ko)
|
2013-04-03 |
2021-03-26 |
엔-폴드 엘엘씨 |
신규 나노입자 조성물
|
|
WO2014165782A2
(en)
|
2013-04-05 |
2014-10-09 |
Massachusetts Institute Of Technology |
Compositions, methods, and kits comprising platinum compounds associated with a ligand comprising a targeting moiety
|
|
AU2014275045A1
(en)
*
|
2013-06-03 |
2015-12-17 |
University Of Southern California |
Targeted crosslinked multilamellar liposomes
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
US10434194B2
(en)
|
2013-06-20 |
2019-10-08 |
Case Western Reserve University |
PSMA targeted nanobubbles for diagnostic and therapeutic applications
|
|
US9657094B2
(en)
*
|
2013-06-24 |
2017-05-23 |
Colorado School Of Mines |
Biodegradable polymers for delivery of therapeutic agents
|
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
EP3456700A1
(en)
|
2013-10-18 |
2019-03-20 |
Deutsches Krebsforschungszentrum |
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
|
|
US10542918B2
(en)
|
2013-10-23 |
2020-01-28 |
Verily Life Sciences Llc |
Modulation of a response signal to distinguish between analyte and background signals
|
|
US9636034B2
(en)
|
2013-10-23 |
2017-05-02 |
Verily Life Sciences Llc |
Non-invasive analyte detection system with modulation source
|
|
WO2015070210A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
|
EP3533473A3
(en)
*
|
2013-11-14 |
2019-12-18 |
Endocyte, Inc. |
Compounds for positron emission tomography
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
EP3079668A1
(en)
|
2013-12-09 |
2016-10-19 |
Durect Corporation |
Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
|
|
EP3084445B1
(en)
|
2013-12-11 |
2020-10-28 |
University of Massachusetts |
Compositions and methods for treating disease using salmonella t3ss effector protein (sipa)
|
|
JP2017500865A
(ja)
|
2013-12-19 |
2017-01-12 |
ノバルティス アーゲー |
レプチンｍＲＮＡの組成物および製剤
|
|
DK3092256T3
(da)
|
2014-01-10 |
2022-06-20 |
Birdie Biopharmaceuticals Inc |
Forbindelser og sammensætninger til immunterapi
|
|
WO2015120476A1
(en)
*
|
2014-02-10 |
2015-08-13 |
Salk Institute For Biological Studies |
Increasing storage of vitamin a, vitamin d and/or lipids
|
|
PE20170312A1
(es)
|
2014-03-14 |
2017-03-30 |
Pfizer |
Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
|
|
CN103861112B
(zh)
*
|
2014-03-25 |
2015-12-30 |
国家纳米科学中心 |
基于聚合物纳米粒子载体的药物组合物及其制备方法
|
|
KR20160148626A
(ko)
*
|
2014-04-24 |
2016-12-26 |
렌슬러 폴리테크닉 인스티튜트 |
매트릭스 부재 중합체 나노복합체 및 그의 관련 제품 및 방법
|
|
KR102589295B1
(ko)
|
2014-05-14 |
2023-10-13 |
타르그이뮨 테라퓨틱스 아게 |
개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
CN121243402A
(zh)
|
2014-07-09 |
2026-01-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1组合
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN104306332B
(zh)
*
|
2014-09-24 |
2017-02-15 |
东南大学 |
一种喜树碱类磷脂化合物、其药物组合物及应用
|
|
US9968688B2
(en)
|
2014-11-12 |
2018-05-15 |
Verily Life Sciences Llc |
Shielded targeting agents, methods, and in vivo diagnostic system
|
|
US11033637B2
(en)
|
2014-11-21 |
2021-06-15 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
|
US11045428B2
(en)
|
2014-11-21 |
2021-06-29 |
University Of Maryland, Baltimore |
Decreased adhesivity receptor-targeted nanoparticles for Fn14-positive tumors
|
|
US10188759B2
(en)
|
2015-01-07 |
2019-01-29 |
Endocyte, Inc. |
Conjugates for imaging
|
|
US9861710B1
(en)
|
2015-01-16 |
2018-01-09 |
Verily Life Sciences Llc |
Composite particles, methods, and in vivo diagnostic system
|
|
CN107614019A
(zh)
|
2015-03-09 |
2018-01-19 |
加利福尼亚大学董事会 |
用于组合抗癌疗法的聚合物‑药物结合物
|
|
US10758520B1
(en)
|
2015-05-20 |
2020-09-01 |
University Of South Florida |
Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
CA2993823C
(en)
|
2015-07-28 |
2024-01-02 |
Board Of Regents, The University Of Texas System |
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
WO2017053720A1
(en)
*
|
2015-09-25 |
2017-03-30 |
Tarveda Therapeutics, Inc. |
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
|
|
KR102233726B1
(ko)
|
2015-09-30 |
2021-03-31 |
도이체스 크렙스포르슝스첸트룸 |
전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
|
|
US20170128592A1
(en)
*
|
2015-10-01 |
2017-05-11 |
Indian Institute Of Technology, Bombay |
Targeted polymeric nano-complexes as drug delivery system
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
JP7384512B2
(ja)
|
2015-10-22 |
2023-11-21 |
モデルナティエックス インコーポレイテッド |
広域インフルエンザウイルスワクチン
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
AU2016341309A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Cancer vaccines
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
EA201891000A1
(ru)
|
2015-10-22 |
2018-12-28 |
МОДЕРНАТиЭкс, ИНК. |
Вакцина против респираторно-синцитиального вируса
|
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
EP3397643A1
(en)
|
2015-12-30 |
2018-11-07 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Pt(IV) PRODRUGS
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
ES2897983T3
(es)
|
2016-02-15 |
2022-03-03 |
Univ Georgia |
Liposomas cargados con IPA-3 y procedimientos de uso de los mismos
|
|
KR20180112060A
(ko)
|
2016-02-23 |
2018-10-11 |
타베다 세라퓨틱스, 인코포레이티드 |
Hsp90 표적화된 접합체 및 이의 입자 및 제형
|
|
EP3439640B1
(en)
|
2016-04-08 |
2024-01-17 |
The Cleveland Clinic Foundation |
Nanoparticles for drug delivery to treat bone disease
|
|
WO2017192863A1
(en)
|
2016-05-04 |
2017-11-09 |
L.E.A.F. Holdings Group Llc |
Targeted liposomal gemcitabine compositions and methods thereof
|
|
JP6757061B2
(ja)
*
|
2016-05-09 |
2020-09-16 |
東京都公立大学法人 |
ドラッグデリバリー用脂質単層被覆型ナノ粒子
|
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
|
CN106176595B
(zh)
*
|
2016-08-31 |
2019-10-22 |
辰欣药业股份有限公司 |
一种更昔洛韦注射液及其制备工艺
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
TWI781130B
(zh)
|
2017-01-03 |
2022-10-21 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
EP4186888B1
(en)
|
2017-03-15 |
2025-11-26 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
WO2018175273A1
(en)
*
|
2017-03-21 |
2018-09-27 |
The Regents Of The University Of Michigan |
Erg targeted therapy
|
|
US10369230B2
(en)
|
2017-04-06 |
2019-08-06 |
National Guard Health Affairs |
Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
US11485972B2
(en)
|
2017-05-18 |
2022-11-01 |
Modernatx, Inc. |
Modified messenger RNA comprising functional RNA elements
|
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
PL3641730T3
(pl)
*
|
2017-06-22 |
2021-08-23 |
SNBioScience Inc. |
Cząstka i kompozycja farmaceutyczna zawierająca nierozpuszczalną pochodną kamptotecyny z podwójną strukturą rdzenia i powłoki oraz sposób ich wytwarzania
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
EP3655017B1
(en)
|
2017-07-17 |
2025-01-22 |
Medincell S.A. |
Pharmaceutical composition
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
EP3470056B1
(en)
*
|
2017-10-16 |
2022-04-27 |
Medtronic Vascular Inc. |
Therapeutic nanoparticles for treating vascular diseases
|
|
RU2669937C1
(ru)
*
|
2017-10-17 |
2018-10-17 |
федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) |
Фармацевтическая противоопухолевая композиция паклитаксела с гистоном Н1.3 в качестве носителя и способ получения композиции
|
|
US11939601B2
(en)
|
2017-11-22 |
2024-03-26 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
CA3079428A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
EP3714045A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
MA51523A
(fr)
|
2018-01-05 |
2020-11-11 |
Modernatx Inc |
Polynucléotides codant pour des anticorps anti-virus du chikungunya
|
|
CN112040941A
(zh)
*
|
2018-03-15 |
2020-12-04 |
阿托莎医疗公司 |
诱导免疫应答的原位方法
|
|
WO2019183633A1
(en)
|
2018-03-23 |
2019-09-26 |
Case Western Reserve Univeristy |
Psma targeted conjugate compounds and uses thereof
|
|
WO2019191456A1
(en)
|
2018-03-28 |
2019-10-03 |
Greenmark Biomedical Inc. |
Phosphate crosslinked starch nanoparticle and dental treatments
|
|
JP7551110B2
(ja)
*
|
2018-04-06 |
2024-09-17 |
ノース カロライナ ステート ユニバーシティ |
癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達
|
|
EP3773745A1
(en)
|
2018-04-11 |
2021-02-17 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
CN112368024A
(zh)
|
2018-04-17 |
2021-02-12 |
恩多塞特公司 |
治疗癌症的方法
|
|
JP7417958B2
(ja)
*
|
2018-04-23 |
2024-01-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｃｄｋ９阻害薬の局所送達のための徐放製剤
|
|
JP2021523151A
(ja)
|
2018-05-11 |
2021-09-02 |
ホスホレックス、インコーポレイテッド |
負の表面電荷を有するマイクロ粒子及びナノ粒子
|
|
WO2019226650A1
(en)
|
2018-05-23 |
2019-11-28 |
Modernatx, Inc. |
Delivery of dna
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
EA201800477A1
(ru)
*
|
2018-08-28 |
2020-02-28 |
Ооо "Нпк Альфа-Онкотехнологии" |
Препарат для лечения онкологических заболеваний
|
|
WO2020047201A1
(en)
|
2018-09-02 |
2020-03-05 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
MX2021003015A
(es)
|
2018-09-13 |
2021-07-15 |
Modernatx Inc |
Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
|
|
WO2020056155A2
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
|
JP2022500444A
(ja)
|
2018-09-14 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3856233A1
(en)
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
US12286612B2
(en)
*
|
2018-12-31 |
2025-04-29 |
Saint-Gobain Performance Plastics Corporation |
Containers containing degradable carriers
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
WO2020150740A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Case Western Reserve University |
Psma ligand targeted compounds and uses thereof
|
|
WO2020191305A2
(en)
|
2019-03-20 |
2020-09-24 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
JP2022532078A
(ja)
|
2019-05-08 |
2022-07-13 |
アストラゼネカ アクチボラグ |
皮膚及び創傷のための組成物並びにその使用の方法
|
|
CN114096264B
(zh)
|
2019-05-20 |
2025-03-14 |
因多塞特股份有限公司 |
制备psma缀合物的方法
|
|
AU2020292246A1
(en)
|
2019-06-12 |
2022-01-27 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to bone morphogenetic protein 6
|
|
WO2020252455A1
(en)
|
2019-06-13 |
2020-12-17 |
The General Hospital Corporation |
Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
|
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
CN114072446B
(zh)
|
2019-08-09 |
2025-05-13 |
生物辐射实验室股份有限公司 |
聚合物点
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
CA3163503A1
(en)
|
2019-12-03 |
2021-06-10 |
Onselex Pharmaceuticals, Inc. |
Polyphosphazene drug carriers
|
|
CN115428088A
(zh)
|
2020-02-13 |
2022-12-02 |
10X基因组学有限公司 |
用于基因表达和dna染色质可及性的联合交互式可视化的系统和方法
|
|
WO2021183318A2
(en)
*
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
CA3173528A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
EP4158005A1
(en)
|
2020-06-01 |
2023-04-05 |
ModernaTX, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
CA3181680A1
(en)
|
2020-06-12 |
2021-12-16 |
University Of Rochester |
Encoding and expression of ace-trnas
|
|
US12521435B2
(en)
|
2020-07-03 |
2026-01-13 |
Case Western Reserve University |
Photodynamic therapy composition
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
CA3189601A1
(en)
|
2020-07-24 |
2022-01-27 |
The General Hospital Corporation |
Enhanced virus-like particles and methods of use thereof for delivery to cells
|
|
KR20230084476A
(ko)
|
2020-10-08 |
2023-06-13 |
타르그이뮨 테라퓨틱스 아게 |
암의 치료를 위한 면역요법
|
|
WO2022104131A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
AU2021403156A1
(en)
*
|
2020-12-18 |
2023-07-13 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
WO2022150356A1
(en)
*
|
2021-01-06 |
2022-07-14 |
Florida Atlantic University Board Of Trustees |
Cancer treatment regimen using anti-parasitic compounds and gut microbiome modulating agents
|
|
CA3205846A1
(en)
|
2021-01-25 |
2022-07-28 |
Yinglin GAO |
Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
|
US20240226025A1
(en)
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
US20240207374A1
(en)
|
2021-03-24 |
2024-06-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
US20240216288A1
(en)
|
2021-03-24 |
2024-07-04 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
US20240263195A1
(en)
|
2021-05-11 |
2024-08-08 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
|
EP4355882A2
(en)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
WO2023059809A2
(en)
*
|
2021-10-06 |
2023-04-13 |
The Regents Of The University Of California |
Methods and agents for prevention of viral proliferation
|
|
WO2023079142A2
(en)
|
2021-11-05 |
2023-05-11 |
Targimmune Therapeutics Ag |
Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
|
|
US20250332265A1
(en)
|
2021-11-09 |
2025-10-30 |
Case Western Reserve University |
Psma targeted conjugate compounds and uses thereof
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
AU2023215397A1
(en)
|
2022-02-07 |
2024-08-22 |
University Of Rochester |
Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
US20250221931A1
(en)
|
2022-03-25 |
2025-07-10 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
IL320618A
(en)
|
2022-11-07 |
2025-07-01 |
Targimmune Therapeutics Ag |
Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
|
|
IL320615A
(en)
|
2022-11-07 |
2025-07-01 |
Targimmune Therapeutics Ag |
PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials
|
|
US20260000700A1
(en)
|
2022-11-07 |
2026-01-01 |
Targimmune Therapeutics Ag |
Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
|
|
CN115844822B
(zh)
*
|
2022-11-23 |
2024-05-14 |
上海交通大学医学院附属第九人民医院 |
一种口服载药胶束组合物及其制备方法
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
KR20250155004A
(ko)
|
2023-02-23 |
2025-10-29 |
유니버시티 오브 로체스터 |
폐쇄 말단 dna 가닥 분자를 제조하기 위한 제제 및 방법
|
|
WO2024182301A2
(en)
|
2023-02-27 |
2024-09-06 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
EP4704816A1
(en)
|
2023-05-03 |
2026-03-11 |
ModernaTX, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2025042806A2
(en)
|
2023-08-21 |
2025-02-27 |
Modernatx, Inc. |
C-met binding antibodies, nucleic acids encoding same, and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
CN117683372A
(zh)
*
|
2023-10-14 |
2024-03-12 |
江苏荣耀光学科技有限公司 |
一种纳米光热试剂及其制备方法与应用
|
|
WO2025101685A1
(en)
|
2023-11-09 |
2025-05-15 |
University Of Rochester |
Suppression of nonsense mutations using anticodon engineered (ace)-trnas
|
|
WO2025238236A1
(en)
|
2024-05-16 |
2025-11-20 |
Targimmune Therapeutics Ag |
Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol
|
|
WO2025255199A1
(en)
|
2024-06-05 |
2025-12-11 |
Modernatx, Inc. |
Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
|
|
WO2026006151A2
(en)
|
2024-06-24 |
2026-01-02 |
University Of Rochester |
Functionalization of ace-trna encoding synthetic linear picovectors
|
|
WO2026030209A1
(en)
|
2024-07-29 |
2026-02-05 |
University Of Rochester |
Use of decoding trnas to boost protein expression or function
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026044055A1
(en)
|
2024-08-23 |
2026-02-26 |
Modernatx, Inc. |
Muc16 binding molecules, nucleic acids encoding same, and methods of use
|
|
WO2026075820A1
(en)
|
2024-10-03 |
2026-04-09 |
Modernatx, Inc. |
4-1bb binding molecules, nucleic acids encoding same, and methods of use
|